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ROUTINE ANAL CYTOLOGY SCREENING FOR ANAL DYSPLASIA IN AN ETHNICALLY 
DIVERSE URBAN HIV CLINIC 
Hyman Scott, Joe Khoury, Brent A. Moore, and Sharon Weissman. Section of Infectious Disease, 
Department of Internal Medicine, Hospital of Saint Raphael, New Haven, CT. (Sponsored by David Katz, 
Department of Epidemiology and Public Health, Yale School of Medicine.) 
Anal cancer, like cervical cancer, is associated with Human Papillomavirus (HPV) infection.  HIV+ 
patients have 38-60 fold increased risk of anal cancer compared to HIV- patients prompting many to 
suggest routine screening given the success of cervical Pap screening.  Our goal is to describe our 
experience with routine anal Pap screening, determine which patients are most likely to have abnormal 
results, if anal disease on physical exam is predictive of cytology, and correlate cytology with histology 
findings.  Charts of all patients with an anal Pap followed at the Hospital of Saint Raphael HIV Clinic were 
reviewed.  Demographics, immune status, sexually transmitted disease history, cytology and histology data 
was extracted from medical charts.  Patients with an anal Pap between November 1, 2002-November 30, 
2004 were included.  Those with an insufficient sample were excluded.  Analysis was done using χ2 for 
comparison of proportions and student t-test for continuous variables.  Overall, 265/560 HIV+ patients had 
at least one anal Pap.  Seventy-four of these 265 patients had an abnormal anal Pap.  Mean age was 44 yrs, 
and 68% were men. Fifty-nine percent were African American, 34% White, and 17% Hispanic.  Those with 
an abnormal Pap were more likely to be White (p=.03), and be gay or bisexual men (p=.02).  They were 
also more likely to have lower CD4+ nadir (142 vs 223, p=.005) and CD4+ at time of anal Pap (353 vs 497, 
p<.001).  Those with an abnormal anal Pap also had more anal disease (30% vs 9%, p<.001), history of 
warts (23% vs 12%, p=.02) and herpes (35% vs 22%, p=.02).  Anal disease on physical exam had a 
sensitivity of 56% and specificity of 77% for abnormal cytology findings.  On histology two patients had 
Anal Intraepithelial Neoplasia  (AIN ) I, 2 AIN II, 3 AIN III, and 2 Squamous Cell Carcinoma In Situ.  
There was no correlation between cytology and histology.  Routine anal cytology screening is a feasible 
tool to incorporate into an ethnically diverse HIV clinic for identifying precancerous anal lesions, a group 
which has been largely overlooked.  Anal disease on physical exam is a poor predictor of abnormal 
cytology and there was no correlation between severity of disease on cytology and histology.  However, 
further follow-up study is required to determine the impact on morbidity and mortality. 
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Introduction 
Since the advent of Highly Active Antiretroviral Therapy (HAART) there has 
been a significant decline in mortality and morbidity in western countries due to Human 
Immunodeficiency Virus (HIV) (1).  Despite this improvement in the health of those 
infected with HIV, there are approximately forty thousand new infections each year in the 
United States (2).  As many of these patients receive appropriate therapy and 
opportunistic infection prophylaxis, they are living longer with HIV and an incompletely 
reconstituted immune system.  As a result, they are at increased risk for development of 
malignancies that have not historically been associated with HIV infection or Acquired 
Immunodeficiency Syndrome (AIDS) (3). 
 Since the early stages of the AIDS epidemic, an increased risk of malignancy has 
been associated with HIV infection.  Two malignancies, Kaposi’s sarcoma and primary 
CNS lymphoma, are currently part of the CDC’s surveillance definition of AIDS (4). 
HIV positive women are at increased risk for invasive cervical cancer.  Thus invasive 
cervical cancer was added to the case definition of AIDS in 1993 (4).  Two of these 
diseases are strongly associated with viral infections, Human Herpes Simplex Virus 
(HHSV) 8 and Human Papillomavirus (HPV) for Kaposi’s sarcoma and invasive cervical 
carcinoma respectively (5, 6).  CNS lymphoma has been associated with Epstein Barr 
Virus (7).  The role of HPV in the development of cervical cancer has been extensively 
studied in developed nations. 
Human Papillomavirus and Cervical Cancer 
Human Papillomavirus is an epitheliotropic virus and while initially included in 
the broader group of polyomaviruses, they were found to be molecular distinct with later 
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molecular study (8).  Currently there are more than one hundred genotypes of HPV which 
have been identified according to divergence in three of the virus’s known genes, E6, E7, 
and L1.  The classification of the different genotypes is dependent on the differences 
between the structural (L1 and L2) and the non structural genes (E1, E2, E4-E7).  
Genotype classification is based on 10% or greater divergence from known genotypes.  
Several of the genotypes have been classified as low, intermediate, and high risk in 
accordance with the degree of demonstrated oncogenicity.  HPV has tropism for the 
cervical transitional zone where the epithelium transitions from columnar to squamous.  
It is within the transitional zone that the cervical dysplasia occurs and the site of targeted 
local excisional therapy.  The most common high risk HPV types found in high cervical 
lesions are 16 and 18; however, other HPV types including 31 and 33 have also been 
associated with cervical dysplasia. 
 The natural history of HPV infection of the female genital tract has been 
elucidated primarily by cross-sectional and longitudinal studies (9-12).  HPV infection in 
the female genital tract is fairly uncommon until women become sexual active during late 
adolescence or early adulthood.  In the US, population prevalence studies have 
demonstrated that up to 10-20% of women between the ages of 15-49 have molecular 
evidence of infection (13).  It is estimated that greater than 90% of these infections are 
subclinical, latent, or have been cleared (14).  Cohort studies among college women 
found that high rates of women acquired HPV at some point during college (15, 16).  
However, only 9% of these women had persistent infection after two years of follow-up 
(16).  Among those who developed cytological lesions, lesions often regressed and there 
is often spontaneous clearance of the virus (17).  This is reflected in the declining 
 3
prevalence of HPV infection in middle-aged women (18).  Although the occurrence of 
spontaneous cervical HPV clearance has been documented, its exact mechanism is 
unknown. 
 Despite this high rate of clearance, it’s estimated that 10-70% of women with 
confirmed dysplastic lesions will eventually progress to high grade lesions or invasive 
cervical cancer depending on the initial lesion severity (19).  Although less than 25% of 
women with high grade cervical lesions will progress to invasive cervical cancer, it 
appears that the persistent presence of HPV is a common risk factor for this eventual 
progression (20, 21). These lesions are often associated with the known high risk HPV 
types 16 and 18 (22, 23).  The association between HPV infection, especially of high risk 
genotypes, and cervical cancer has been recognized and cervical cancer is now widely 
viewed as a sexual transmitted disease (11, 24, 25).  Indeed, high risk type HPV infection 
and cervical cancer share many of the same risk factors of early first sexual intercourse, 
multiple sexual partners, and smoking (26).  Fairly early in the epidemic, HIV induced 
immunosuppression has been associated with an increased risk of cervical cancer.  This 
association led to the inclusion of invasive cervical as an AIDS defining diagnosis in the 
CDC 1993 revised AIDS Surveillance case definition. 
 The increased risk of cervical dysplasia and squamous cell carcinoma among HIV 
positive women has been well documented in the literature (27, 28).  In one prevalence 
study, HIV positive women were found to have significantly higher rates of cervical 
lesions than HIV negative women, 26.5% and 7.5% respectively (28).  HIV positive 
women who were more immunosuppression (CD4+ <200 cells/ml) had the highest rates 
of dysplasia.  Although they were unable to demonstrate a significant direct interaction 
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between HPV and HIV, persistent HPV infection likely partially explains these increased 
rates of cervical dysplasia.  Sun and colleagues showed that among a cohort of women in 
New York City that 56% of HIV positive women were HPV positive at initial 
examination compared to 31% of HIV negative women (29).  Among these women, 24% 
of the HIV positive women had persistent infection (same HPV type detected on two or 
more examinations) compared to only 4% of HIV negative women.  The HIV positive 
women also had higher rates of high risk HPV types 16 and 18 compared to their HIV 
negative counterparts.  In their multivariate analysis HIV positive women, including 
those with CD4 counts above 500 cells/ml, being unmarried and having a history of 
injection drug use were all associated with an increase risk of persistent HPV infection.  
In addition to persistent infection, there is evidence that higher levels of high risk HPV 
viral replication occur in HIV positive women with dysplasia (30).  The role of HIV on 
the increased rates of cervical dysplasia has yet to be elucidated, although it appears that 
it is secondary to immunosuppression and not a direct interaction between the two viruses 
(31).  In addition to the increased prevalence of cervical dysplasia, HIV positive patients 
also have decreased rates of regression.  Together, these factors have likely contributed to 
the higher rates of advanced cervical dysplasia and carcinoma in HIV positive women.   
Although the rates in the general population have been relatively low since the 
introduction of routine screening, HIV positive women have continued to carry an excess 
burden of disease.  Serraino and colleagues analyzed data from two European 
longitudinal databases, both part of a cohort of HIV positive women followed-up as part 
of a HIV Seroconverter Study (32).  They found ten cases of invasive cervical carcinoma 
(ICC) among 2141 HIV positive women with an expected incidence of less than one.  No 
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cases were identified among the 811 HIV negative women.  Eight of these ICC cases 
were among HIV positive intravenous drug users.  Similar increased rates have been 
described in the United States (33).  However, in another US prospective study of women 
with or at risk for HIV infection, which included biannual Pap smears, only one incident 
case of ICC was found during 8260 woman-years of follow-up (34).  Despite this 
controversy over prevalence, HIV positive women with cervical neoplasia have poorer 
outcomes and more relapse after therapy (35, 36). 
 Unlike the other AIDS associated malignancies, there has been debate over the 
effect of HAART in the incidence and natural history of cervical dysplasia.  In a cohort 
study of women in several US cities followed with cervical Pap smears every six months, 
Minkoff and colleagues examined the impact of being on HAART on the short-term (at 6 
months follow-up) cytological progression or regression of cervical lesions (37).  They 
found that women who had initiated HAART were more likely to have regression of their 
lesions and less likely to have progression after adjusting for CD4 count and cervical Pap 
smear status.  The positive impact on regression of cytological diagnosed lesions was 
confirmed by Ahdieh-Grant and colleagues who also found that HAART was associated 
with an increased likelihood of regression of lesions (38).  However, they also noted that 
the majority of lesions did not regress to normal, even among those on HAART.  
 Several other studies have not demonstrated the beneficial effect of HAART on 
cervical dysplasia and invasive cervical cancer  (3, 39-41).  In a cohort of HIV positive 
women treated for a mean of 15.4 months, Lillo and colleagues did not find a difference 
in progression of cervical lesion between those receiving HAART and those who were 
not (42).  Patients receiving HAART in this study experienced a significant increase in 
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CD4 count although no significant decrease in HIV viral load was noted.  This was likely 
explained by the fact that those who were treated were often HAART-experienced at time 
of enrollment.  Furthermore, in a meta analysis of twenty-three cohort studies with 1000 
or more patients each, there was no trend toward a decrease in the incidence of cervical 
cancer after the introduction of HAART (41).  A small study by Durruci and colleagues 
examined the incidence of invasive cervical cancer in an Italian cohort of women with 
known HIV seroconversion dates (39).  Although there were only six cases of ICC, they 
found a significant increase in the number of cases during the two year post-HAART era. 
Anal Cancer 
 The role of HPV in the development of cervical cancer has pointed toward the 
possibility of its role in the development of other anogenital cancers, notable anal 
carcinoma.  Anal carcinoma shares many similarities with cervical cancer in anatomy and 
histology as well as its association with HPV infection (43-45).  Anal cancer arises at the 
dentate line where the columnar epithelium transitions to squamous within the anal canal.  
Despite early opinion that anal cancer was secondary to chronic inflammation, there is 
considerable evidence that like cervical cancer it is caused by HPV infection (46-49).  
Initial reports demonstrated those with anal cancer had an increased risk of having had 
anal warts or other STDs (44).  In addition, women with a history of cervical cancer have 
an increased risk for developing anal carcinoma.  This risk has also been associated with 
the same high risk HPV subtypes as cervical cancer. 
 Among the general population, anal cancer is relatively rare with women having 
higher incident rates than men.  Annual incident rates range between 0.9-1.3/100000 for 
women and 0.3-0.7/100000 for men (50-52).  In addition to the increased risk of anal 
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cancer among women with a history of cervical cancer there has also been an increased 
risk of anal cancer among men who have sex with men (MSM) prior to the AIDS 
epidemic.  Indeed while 8% of anal cancer cases were among MSM during 1959-67, this 
rose to 72% during 1978-86 (53).  The current estimated incidence is 37/100,000 among 
men with a history of receptive anal intercourse and is estimated to be approximately 
twice as high among the same group of men who have HIV (51, 52, 54). 
Although, anal intercourse has been implicated as increasing the risk of anal 
cancer, its exact causative role has been questioned.  Frisch and colleagues conducted a 
population-based case control study to determine the role of sexual practices in the 
development of anal cancer in Denmark and Sweden (44).  Women with more sexual 
partners and a history of anal intercourse were at higher risk for anal cancer compared to 
control patients with adenocarcinoma as well as the general population.  Among men, 
there was a positive correlation between increasing number of sexual partners and risk of 
anal cancer, regardless of sexual practice.  Approximately 90% of the cases and controls 
were positive for HPV and 73% of these cases had high risk HPV type16.  Although they 
found a history of anal sex increased the risk for anal cancer, most men and women who 
had anal cancer in this study did not engage in anal sex. 
In addition, the presence of anal HPV infection in heterosexual men and women 
with no history of anal intercourse appears to point to another possible mechanism for 
anal HPV acquisition.  Among heterosexual men with HPV positive female partners, 8% 
had anal HPV detectable (55).  Furthermore, as many as 33% of heterosexual men 
presenting to a clinic with current or history of anal warts had clinical evidence of anal 
HPV infection (56).  This relatively high infection rate was not correlated with receptive 
 8
anal intercourse or anodigital insertion.  Although, HPV infection in the absence of 
obvious risk factors among heterosexual men and women implicates a potential field 
effect for infection, other studies have receptive anal intercourse in men as a risk factor 
(57-59).   
Increased rates of anogenital cancer among renal allograft recipients first 
implicated the role of immunosuppression on cancer development.  These patients have 
an 100 fold increased rate compared to the general population (60).  High prevalence of 
HPV infection and multiple infections likely play an early role in this carcinogenesis 
(61).  A similar association has been noted among HIV positive patients.   
As noted earlier, increased rates of anal cancer were initially seen prior the 
beginning of the AIDS epidemic (59).  During this time, a population based open-cohort 
study of never-married men in San Francisco demonstrated an increase in incidences of 
Kaposi’s sarcoma and non-Hodgkin’s lymphoma (59).  The incidence of anal cancer was 
9.9 times higher than expected during the period 1973-1979 and 10.1 times higher during 
1988-1990.  The increased incidence among a population with a large number of MSM 
prior to the AIDS epidemic suggest that there was an increased rate of HPV transmission 
in a high risk sexual group.  However, in a study by Melbye and colleagues comparing 
AIDS registries and cancer registries found an increased relative risk of 63.4 for those 
with AIDS compared to the general population (62).  Among those with AIDS, MSM had 
a relative risk of 84.1 and non-MSM of 37.7.  Despite these large relative risks, the 
study’s primary limitation was the small number of cases (31 anal cancer, 8 anorectal 
cancer).  Other studies have supported these findings and also demonstrated increased 
rates of anal cancer among HIV positive men (58, 63).  Palefsky and colleagues 
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demonstrated that 36% of HIV positive MSM had anal dysplasia compared to only 7% of 
HIV negative men (63).  Identified risk factors associated with anal dysplasia were high 
levels HPV infection with oncogenic subtypes and reduced CD4 levels.  Interestingly, 
among HIV positive men, significant risk of anal dysplasia was seen in the absence of 
severe immune suppression.  Similarly, Critchlow et al demonstrated among a group of 
homosexual and bisexual men with initial negative cytologic and anoscopy findings that 
HIV positive men had higher rates of anal dysplasia compared to HIV negative patients 
(15.2% vs 5.4%) (58).  They also were able to demonstrate HIV infection as an 
independent risk factor for development of anal dysplasia after controlling for HPV 
infection.   
Increased rates of high risk HPV subtypes appear to partially explain this 
increased risk among HIV positive MSM.  These men are more likely to have infections 
with multiple HPV types, acquire new HPV infections, and have less spontaneous 
clearance of HPV infection (64).  In a community based longitudinal study, Critchlow 
and colleagues found that HIV positive men had higher rates of high-risk HPV subtypes 
(16, 18, 45, or 56) as well as higher HPV viral loads compared to HIV negative men.  
HIV seropositivity, however, was not associated with increased rates of low or 
intermediate risk HPV subtypes.  HIV positive men where also more than twice as likely 
to acquire a new HPV subtype during follow-up, although this acquisition did not appear 
to be related to increased rates of unprotected receptive anal intercourse.  Furthermore, 
HIV positive men were less likely to clear HPV infection on subsequent follow-up visits 
compared to HIV negative men (13% vs. 45%).  This discrepancy was not related to HPV 
subtype.  Among, HIV positive men HPV persistence was associated with HIV DNA 
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presence in the anal canal and not with CD4+ count.  Other studies have also shown that 
HIV associated immunosuppression increases the risk of anal HPV detection (43, 65, 66). 
Furthermore, HIV positive men are more likely to have progression from low 
grade anal dysplasia to high grade dysplasia than HIV negative men (67-70).  In a study 
by Palefsky and colleagues, HIV positive men had more than two-fold increase in relative 
risk for progression to high grade dysplasia compared to HIV negative subjects and were 
also less likely to have regression of lesions (67).  Although baseline diagnosis of anal 
disease was not predictive of progression, subjects infected with one or more HPV 
subtypes were at increased risk regardless of HIV status.  One cohort study has shown 
that as many as 49% of HIV positive homosexual and bisexual men developed high grade 
anal dysplasia over the course of a four year period compared to 17% of HIV negative 
homosexual and bisexual men (68).  These high grade lesions are thought to be 
precancerous lesions with potential to progress to invasive carcinoma (45, 67, 71). 
 Treatment for anal cancer is limited and outcomes are poor with many patients 
have recurrence of disease (72).  Surgical intervention was initially the treatment 
modality of choice and included local resection for limited disease and abdominal 
peritoneal resection with colostomy for more advanced disease.  Although abdominal 
peritoneal resection was associated with significant morbidity, local resection is limited 
by inability to achieve complete resection and subsequent recurrence of disease (73).  
More recently, chemotherapy and radiation individually and in combination are being 
used with varying degrees of success (74, 75).  However, combination therapy outcomes 
appear to be poorer among HIV positive patients, especially in the setting of severe 
immunosuppression (76-78). 
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 Similar to cervical cancer, there is controversy on the impact of HAART on anal 
carcinoma with many of the studies limited by small sample size (79, 80).  While Stadler 
and colleagues found a trend toward better outcomes in patients on HAART, there results 
were not significant.  Linking cancer and AIDS registries, Diamond and colleagues found 
that anal cancer rates increased from 49/100,000 in the pre-HAART era to 122/100,000 
in the post-HAART era (81).  Although patients in the post-HAART era were as 
immunocompromised as the patients in the pre-HAART era, they had a longer duration 
of HIV diagnosis.  It is likely that this longer immunosuppression allows prolonged HPV 
infection resulting in greater risk of carcinogenesis.  Furthermore, patients that had been 
receiving HAART for a median of 32 months had similar rates of anal dysplasia 
compared to those not on HAART, despite immune recovery (82). 
Routine cervical Papacounia (Pap) smear screening has been associated with a 
significant decrease in the incidence of cervical cancer from 40-50/100,000 to 
approximately 9.7/100,000 (83).  Based on the success of the cervical cancer screening 
program many experts have suggested  that routine anal cytology (anal Pap) screening 
should be performed on high risk individuals to detect and remove precancerous anal 
lesions (similar to the cervical Pap model) (84-86).  It has been shown to be a cost-
effective procedure with benefit comparable to other preventative medical protocols used 
in HIV care (87, 88). 
Although most available data on anal carcinoma is for homosexual and bisexual 
men there is also an increased incidence among patients without a history of receptive 
anal intercourse (69, 89).   As much of the evidence for anal cancer screening programs is 
among HIV positive MSM, there is not substantial data on anal dysplasia and anal cancer 
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screening in a diverse population of HIV positive patients seen in an urban HIV clinic.  
Our goals are to describe our experience with a routine anal Pap screening program in an 
urban HIV positive population, to determine if anal disease on exam is predictive of 
abnormal anal Pap findings, and if abnormal cytology correlates with anoscopy and 
histology findings. 
 
Materials and Methods 
This study was conducted with the approval of the Institutional Review Board, 
Hospital of Saint Raphael and the Human Investigations Committee, Yale School of 
Medicine. In November 2002 we implemented an anal cancer screening program, using 
anal Paps, into our HIV clinical care.  All HIV positive patients seen at the Haelen Center 
were offered anal Pap smears as part of routine clinical care (Figure 1).  Briefly, an anal 
Pap is performed using a moistened Dacron swab. The swab is inserted 2-3 cm into the 
anal canal to reach the anal verge. The swab is rotated 360 degrees as it is pulled out.  
After removal the sample was smeared onto a glass slide and fixative immediately 
applied.  All cytology samples were read by one pathologist trained in interpreting anal 
cytology at Hospital of Saint Raphael Pathology Department and reported as one of the 
following: negative for dysplasia, Atypical Cells of Undetermined Significance 
(ASCUS), Anal Intraepithelial Neoplasia (AIN) I, AIN II, or AIN III.   The cytology 
reports interpreted as AIN were recoded as Low-grade Squamous Intraepithelial Lesion 
(LSIL) for AIN I and High-grade Squamous Intraepithelial Lesion (HSIL) for AIN II and 
AIN III.  Patients with abnormal anal Pap findings, classified as ASCUS or greater, were 
referred for surgical follow-up or received another screening anal Pap.  Patients with an 
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abnormal anal cytology received high resolution anoscopy with biopsy of any obvious 
lesions seen with addition of 3% acetic acid.  All samples were imbedded in paraffin for 
routine histopathologic examination.  Biopsy results were reported as AIN I, AIN II, AIN 
III, or Squamous Cell Carcinoma In Situ (SCCIS) using Bethesda Staging criteria.  We 
then retrospectively reviewed charts on all HIV positive patients that received anal Pap 
smears in the Haelen Center at Hospital of Saint Raphael between November 2002 and 
November 2004. 
Medical Record Review 
Outpatient medical charts were reviewed for 276 patients with anal Pap smears 
during a two year period between November 2002 and November 2004.  The following 
data was extracted: Demographics [Age, Sex, Race, HIV risk factor(s)], CD4 count, CD4 
nadir, HIV viral load, current use and history of antiretroviral therapy (ART), history of 
herpes simplex virus infection, history of genital warts, anal disease on physical exam, 
history and stage of cervical dysplasia for women, history of any other genital-urinary 
(GU) disease, result of anal Pap smear, and results of high resolution anoscopy findings 
for those patients with abnormal cytology findings.  For patients with more than one anal 
Pap the following additional data was extracted for all subsequent Pap smears: reason for 
additional Pap, decline in CD4 since last anal Pap, and any new GU disease.  Data for all 
patients with an anal Pap smear were coded and entered into a Microsoft Excel 
spreadsheet.  Ten percent of charts were randomly selected and verified by a non-primary 
data collector with <5% variation between independent evaluations.  Surgical follow-up 
data on all patients with abnormal Pap smears were collected beyond November 2004 to 
capture those with delayed surgical evaluation data.  All primary data collection was 
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carried out by Hyman Scott and Joe Khoury, MD; surgical follow-up data was collected 
by Hyman Scott. 
Statistical Analysis 
For those patients with more than one anal Pap the highest grade cytological 
abnormality was used in the analysis.  Eleven patients with insufficient or missing 
cytology results were excluded.  For patients with biopsy results, the highest grade 
histology was used.  The patients with complete high resolution anoscopy results were 
analyzed separately for anal dysplasia risk factors.  Bivariate analysis was done using χ2 
for comparison of proportions and student T-test for continuous variables using SPSS 
software (SPSS Inc, Chicago IL).  Comparisons were considered significant at p<0.05 
(two tailed).  All statistical analysis was carried out by Brent A. Moore, Ph. D. 
 
Results 
Study Population  
During the two year study period, 560 HIV+ patients were seen for at least one 
routine clinical visit (Figure 2).  Two hundred seventy six patients (49%) received at least 
one screening anal Pap during this time.  Eleven patients were excluded from analysis: 
ten for insufficient anal Pap sample and one for missing record data.  Ninety-two patients 
had more than one anal Pap done during the study period.  Of these 92 patients, 72 had 
two anal Paps, 19 patients had three anal Paps, and one patient had four anal Paps.  
Patients had repeat anal Paps for many different reasons.  Fifty-one patients had only 
normal repeat anal Paps as part of annual screening.  Four patients had a repeat Pap after 
an initial Pap showed insufficient sample.  Thirty-four patients had a repeat Pap to 
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follow-up on an original abnormal anal Pap.  Three patients had a repeat anal Pap for an 
undocumented reason.  Table 1 describes the study population of the 266 patients who 
received an anal Pap smear.  The demographics of the patients receiving an anal Pap are 
similar to the demographics of the entire clinic population (data not shown).  Notably 
66% were African-American or Hispanic and only 28% reported MSM as their HIV risk 
factor.  This is an advanced HIV population which is heavily treated with antiretrovirals. 
Normal vs Abnormal Pap Comparison 
Seventy-four of 265 (27.9%) of subjects had at least one abnormal anal Pap smear 
(Figure 2).  Twenty-four (32%) had ASCUS, 45 (61%) had LSIL and 5 (7%) had HSIL.  
The subjects with an abnormal anal Pap smear were significantly more likely to be white, 
have MSM as the HIV risk factor, have a lower CD4 nadir and lower CD4 count, as well 
as be on ART at the time of the anal Pap smear (Table 2).  Forty-nine percent of the 
subjects with an abnormal anal Pap had heterosexual contact listed as their HIV risk 
factor.  Patients with abnormal anal Paps were also more likely have anal disease on 
physical exam at the time of the anal Pap smear although only 30% of the patients with 
an abnormal anal Pap had anal disease on physical exam.  Patients with abnormal Paps 
were also more likely to have a history of HSV or genital warts.  Eighty-four women 
were included in the analysis and there was no significant difference in history of cervical 
dysplasia between those with abnormal anal Paps and those with normal anal Paps.  
However, complete data on cervical Pap smear and colposcopy results were not always 
accessible as many patients received gynecological care at different facilities.  There was 
no difference between those with normal and abnormal anal Paps with respect to age, 
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gender, proportion with undetectable HIV viral load, history of ever having been on 
ART, or history of other GU disease beyond HSV or genital warts.  
Predictive Value of Anal Exam 
Twenty-two of thirty-nine patients had documented anal disease on physical exam 
at time of anal Pap and subsequently had an abnormal anal Pap.  One hundred seventy 
four of two hundred twenty seven patients had no anal disease and a subsequent normal 
anal Pap.  There were 17 patients with anal disease on exam and a normal anal Pap and 
52 patients with no anal disease on exam and an abnormal anal Pap smear.  The 
sensitivity of anal disease on exam for abnormal anal cytology is 56% and specificity of 
77%.  Anal disease on exam has a positive predictive value (PPV) of 30% and a negative 
predictive value (NPV) of 91% for predicting abnormal cytology. 
Abnormal Anal Cytology Follow-up 
As part of the routine screening program, patients with an abnormal anal Pap 
smear were to receive a surgical referral for high resolution anoscopy with biopsy of any 
suspicious lesions.  Fifty of 74 patients (66%) with an abnormal anal Pap smear were 
referred for surgical evaluation (Figure 3).  Of the 24 patients without a surgical referral, 
three patients were diagnosed with another malignancy, two patients moved away, and 
one patient was admitted to an extended care facility.  Referral and follow-up data was 
lacking for the other 18 patients.  Seven patients never showed-up for their surgical 
evaluation.  Sixteen of the patients with a surgical referral did not receive an anoscopy.  
Two of these patients were unable to tolerate the anoscopy and the remaining 14 had 
either an anal exam or a repeat anal Pap.  Fifteen patients had no abnormalities seen on 
anoscopy and three patients had lesions but no biopsy was taken (one patient was 
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pregnant and two for an undocumented reason).  Nine patients had lesions seen on 
anoscopy and histology proven anal dysplasia (Table 3).  Two patients were identified 
with AIN I, two with AIN II, three with AIN III, and 2 patients with squamous cell 
carcinoma in situ (SCCIS).  Of these 9 patients, 8 with HIV risk factor information 
available (100%) were MSM compared to 7 (54%) of those patients with no lesions on 
anoscopy (two patients with no lesion on anoscopy and one patient with dysplasia had no 
HIV risk factor information available).  In addition, 7 (78%) of the patients with biopsy 
proven dysplasia had anal disease on exam compared to 3 (20%) of the patients with no 
dysplasia.  There was no difference between the two groups in age, CD4+ count at time 
of anal Pap, CD4+ nadir, or history of anogenital warts. 
Cytology and Histology Association 
In the follow-up data that was available, there was no association between 
cytology and histology findings (Table 3).  Of the 2 patients with ASCUS on cytology 
who had an anoscopy, one had no lesions seen on anoscopy and the other had SCCIS.  
Similar discrepancies between the cytology and histological findings were seen in 
patients with LSIL and HSIL.   
 
Discussion 
We have demonstrated an ability to institute an anal cancer screening program as 
part of routine HIV care in an ethnically diverse inner city setting.  During the study 
period we screened approximately half (49%) of the clinic population that was seen for 
HIV care which included a substantial number (38%) of women.  Although, current 
recommendations are particularly targeted toward MSM for anal cancer screening, high 
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grade anal dysplasia has been demonstrated in 36% of intravenous drug users who have 
no history of receptive anal intercourse (70).  In our study we found that 17% of patients 
with IVDU and 26% of patients with heterosexual sex as their only recorded HIV risk 
factor had abnormal anal Pap smears.  In addition, 49% of those with an abnormal Pap 
smear had heterosexual contact listed as their HIV risk factor.  This increased rate among 
heterosexual men and women is consistent with other published studies (69, 90).  
However, the risk factors in our study were collected retrospectively and were based on 
coding by providers in clinic charts.  Thus, we may underestimate the number of patients 
who have receptive anal intercourse.  Nevertheless, our experience is more typical of a 
“real world setting” in which providers often do not routinely ask in-depth sexual history.  
We found that patients with an abnormal anal Pap smear were more likely to have 
anal disease on physical exam compared to those with a normal anal Pap smear.  
However, despite a statistically significant difference, only 30% of those with an 
abnormal anal Pap smear had anal disease on physical exam.  The vast majority (70%) of 
patients with abnormal Pap smear findings did not have anal disease at the time of their 
anal Pap smear.  In addition, 17 (9%) of patients with a normal anal Pap had anal disease 
on physical exam.  With a sensitivity of 56%, it would be a poor screening tool for 
determining which patients require routine anal cytology.  Moreover, anal disease on 
physical exam is a poor predictor of abnormal cytology findings with a PPV of 30%.  
However, the absence of anal disease on physical exam had a NPV of 91% indicating that 
a negative anal exam may be a reliable predictor of negative cytology.  Although this 
suggests that a negative anal exam may help identify which patients should receive a 
screening anal Pap, 23% of the patients without anal disease on exam had an abnormal 
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anal Pap.  One explanation for lack of predictive value of anal disease on physical exam 
is that only the perianal area is visible on exam and whereas the anal Pap smear samples 
from within the anal canal, where anal dysplasia occurs within the transition zone.  
Furthermore, given that that HPV is considered the causative agent, the absence of 
obvious warts or other obvious lesions does not preclude the presence of HPV infection 
and epithelial dysplasia. 
The patients with an abnormal anal Pap were also more likely to have a lower 
CD4 nadir and lower CD4 count at the time of the anal Pap smear compared to those with 
a normal anal Pap smear.  Interestingly, these patients were more likely to be on 
antiretroviral therapy which reflects the treatment of their more advanced disease.  
However, although there is controversy whether anal carcinoma is responsive to  highly 
active antiretroviral therapy (HAART), it does not appear to have an impact on anal HPV 
infection (70, 79, 80).  HIV appears to have a local immunosuppressive effect in the anal 
mucosa that is not responsive to HAART even with increases in systemic CD4 counts 
and decrease in HIV viral load (43, 91, 92).  This continued local immune suppression 
may be the mechanism via which HPV leads to anal carcinoma, as the decreased immune 
surveillance by dendritic cells allows transformed cells to grow unchecked (71). 
The percentage of women with an abnormal anal Pap (36%) was proportionally 
equal to the percentage of women screened (32%) in clinic.  It has been shown previously 
that women with a history of cervical dysplasia are at increased risk for developing anal 
dysplasia. We were not able to confirm this in our study, but this may be because cervical 
Pap smear or colposcopy results were not always available.  Many of the women received 
gynecological care at another institution and records were not available for review.  
 20
Of the seventy four patients who were identified with cytological evidence of anal 
dysplasia, only twenty-four received high resolution anoscopy with biopsy of visible 
lesions.  This highlights many of the barriers to instituting a cancer screening program 
into routine clinical care.  The anal Pap smear was easily accepted by the patients and 
patients did not complain of untoward effects from this screening test.  Yet, it was much 
more difficult to insure adherence with surgical anoscopy and biopsy follow-up.  Barriers 
to surgical evaluation included patient-centered difficulties such as the perceived 
intolerability of the anoscopy procedure, fear of a cancer diagnosis, and general 
difficulties with maintaining clinic appointments.  Furthermore, initially, as patients were 
referred for a surgical evaluation, there was confusion about the need and type of 
evaluation these patients required.  Some patients were receiving high resolution 
anoscopy and aceto-whitening with biopsy of dysplasic lesions, while others received an 
anal exam or repeat anal Pap smear.  With ongoing education to our surgical residents 
and focusing the anal dysplasia follow-ups to one clinic day a week (two clinic 
attendings) we  were able to overcome this barrier although this led to a significant delay 
in follow-up (85, 93, 94).  Lastly, even though the anal Pap smear was well accepted by 
patients only half the patients seen were actually screened.  This is at least partly do to the 
complexity and advanced HIV disease stage of our patients.  If other more urgent medical 
or HIV related problems were apparent (such as newly diagnosed malignancy), these 
would take priority and management of their anal disease would become a secondary 
issue.  Despite these barriers, during the course of the screening program two patients 
(0.7%) were identified with squamous cell carcinoma in situ. These two patients have 
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been successfully treated with local therapy.  They are currently being followed and are 
disease-free almost two years later. 
Our data did not show consistency between cytology and histology findings.  The 
three patients with HSIL on cytology had no lesions seen on anosocopies and the two 
patients with SCCIS on biopsy had ASCUS and LSIL on cytology, respectively.  This 
finding is consistent with other published reports (85, 95).  Palefsky et al have shown that 
anal Pap smear screening in gay and bisexual men has a positive predictive value of 38% 
and negative predictive value of 84% when ASCUS was included as abnormal as was 
done in with our study.  The positive predictive value of the exam was driven by the 
higher disease prevalence in this patient population.  In our study, only 38% of patients 
self-identified as gay or bisexual as their HIV risk factor so the positive predictive value 
of the anal Pap smear screening program would likely be lower.  Given that all the 
patients with high grade lesions on histology were patients with ASCUS or LSIL, this 
study supports the recommendation of surgical evaluation of any patient with 
abnormalities, including ASCUS.  One limitation is that only approximately thirty-two 
percent of the patients with abnormal cytology did not received anoscopy with biopsy.  
The majority of patients that did not receive an anoscopy were those with low grade 
cytological lesions.  Other limitations of this study include its retrospective nature and the 
temporal distance between the anal Pap smear and anoscopy. 
Of the twenty-four patients with anoscopy and biopsy, all those with histological 
confirmed dysplasia were gay or bisexual men and had higher rates of anal disease on 
physical exam than those with normal anoscopy findings.  Given that all those with 
histological proven dysplasia were gay or bisexual men is telling, although this represents 
 22
only thirty percent of those with abnormal cytology.  Since men with a history of 
receptive anal sex are at the increased risk for development of anal dysplasia, it is 
expected that a higher percentage of patients with anal dysplasia would be gay or 
bisexual men.  However, since there are data that show a significant percentage of HIV 
positive men without a history of receptive anal sex also have anal dysplasia, routine 
screening is still warranted among those who do not self-identify as gay or bisexual (69).  
More follow-up data would be required to determine the predictive value and utility of 
screening an entire HIV population if MSM are the only patients who have histology 
confirmed anal dysplasia. 
In summary, we were able to institute anal Pap smear screening as part of routine 
HIV care in an urban HIV clinic setting with diverse risk factors.  The anal Pap smear 
was easy to do and well tolerated by patients.  Anal exam proved to be a poor predictor of 
those with cytological evidence of dysplasia.  Anal cancer screening should be performed 
on all HIV patients regardless of HIV risk factors and gender.  Although only MSM were 
found to have histological evidence of dysplasia in our study, full follow-up evaluation of 
all patients with abnormal anal Pap smears is needed.  Despite the identification of those 
with anal dysplasia via the screening program, its impact on morbidity and mortality of 
patients remains unknown, and warrants further study. 
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Figure 1: Anal Intraepithelial Neoplasia Screening Program*
Patients were offered routine anal Pap smear screening and the above protocol was used 
for follow-up or further evaluation. 
ASCUS-Atypical Cells of Undetermined Significance; LSIL-Low-grade Squamous 
Intraepithelial Lesion; HSIL- High-grade Squamous Intraepithelial Lesion; Bx-Biopsy; 
AIN- Anal Intraepithelial Neoplasia; SCCIS-Squamous Cell Carcinoma In Situ. 
* *Adapted from Chin-Hong and Palefsky CID 35:1127-1134 
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Figure 2: Total Number of Patients Screened During Two Year Study Period. 
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Figure 3: Surgical referral and evaluation of the 74 patients with at least one 
                 abnormal anal Pap. 
* These two patients were unable to tolerate anoscopy. 
** These patients had an anal exam and/or a repeat anal Pap. 
Surg Referral-Surgical Referral, Surg Eval-Surgical Evaluation,  
AIN- Anal Intraepithelial Neoplasia 
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Table 1: Baseline demographics of the patients screened during the study period. 
 
Baseline Characteristics  
Mean Age (range) 44.1 yrs (26-77) 
Gender  68% Male 
Race 49% African American 
34% White 
17% Hispanic 
HIV Risk Factors 49% Heterosexual 
28% MSM 
18% IVDU 
% on ART 75% 
% ever on ART 91% 
Mean CD4 Nadir (sd) 201 (206) 
% CD4 Nadir <200 59% 
Mean CD4 at Pap (sd) 458 (323) 
% CD4 <200 20% 
% with undetectable VL  
(<400 copies/ml) 
57% 
Mean VL at Pap (sd) 46,844 (153,577) 
MSM-Men who have sex with men; IVDU-Intravenous Drug Use; ART-HIV 
Antiretroviral therapy; Undetectable VL-Undetectable HIV Viral Load
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Table 2: Comparison of patients with normal or abnormal anal Paps by age, race, 
               sex, HIV risk factor, immune status, history of sexually transmitted 
               disease, anal disease, and history of cervical dysplasia for women. 
 
Characteristic 
Normal 
(n=191) 
Abnormal
(n=74) p-value
Mean Age (SD) 44.6 (9.0) 42.6 (8.3) 0.10 
Race 
    % White 
    % African American 
    % Hispanic 
 
30% (57) 
54% (103) 
16% (31) 
 
45% (33)
35% (26)
19% (14)
0.03 
Male 69% (133) 64% (48) 0.49 
HIV Risk Factor 
    MSM 
    IVDU 
    Heterosexual 
 
25% (45) 
22% (39) 
53% (95) 
 
40% (29)
11% (8) 
49% (34)
0.02 
CD4 Nadir mean (SD) 223 (211) 142 (185) 0.005
CD4 Nadir <200 53% (100) 76% (56) 0.001
CD4 at Pap 497 (331) 353 (274) <0.001
CD4 Pap <200 14% (27) 37% (27) <0.001
 VL <400 57 % (109) 63% (46) 0.33 
Anal Disease 9%(17) 30%(22) <0.001
ART at Pap 70%(135) 85%(63) 0.02 
ART ever 89%(171) 96%(70) 0.10 
History of HSV 22%(42) 35%(26) 0.02 
History of Anogenital Warts 12%(23) 23%(17) 0.02 
Other GU disease 35%(68) 30%(22) 0.42 
History of cervical dysplasia 
(n =84) 
50%(29) 46%(12) 0.74 
P<0.05 considered significant. 
MSM-Men who have sex with men; IVDU-Intravenous Drug Use; VL- HIV Viral Load; 
ART-HIV Antiretroviral therapy; HSV-Herpes Simplex Virus; GU-Genitourinary disease
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Table 3: Comparison of cytological results to histological results for the 24 patients 
    with complete anoscopy results.   
 
      Anoscopy    
Cytology No lesions 
seen on 
anoscopy 
AIN I AIN II AIN III SCCIS
ASCUS 1 0 0 0 1 
LSIL 11 2 2 3 1 
HSIL 3 0 0 0 0 
 
 
 
 
 
 
 
ASCUS-Atypical Cells of Undetermined Significance; LSIL-Low Grade Squamous 
Intraepithelial Lesion; HSIL-High Grade Intraepithelial Lesion; AIN-Anal Intraepithelial 
Lesion; SCCIS-Squamous Cell Carcinoma in Situ. 
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APPENDIX 
 
Anal Pap Data Collection Sheet #1 
1. Reviewer/  
1a. Date of review:    
1. 
1a. 
2. Study Number: 2. 
3. Age at Pap (years): 3. 
4. Race:  1= White  2=AA  3= Hispanic  4=Asian   5=native American  6=Other 4. 
5. Sex:   1=male   2=female 5. 
6. HIV Risk Factor:  1=homo/bisexual  2=MSM/IDU  3=IDU  4=hetero 
5=hetero/IDU  6=Transfusion  7=unknown 
6. 
7. CD4 nadir: 7. 
8. Date CD4 nadir: 8. 
9. CD4 at Anal Pap Test 9. 
10. Date CD4 from item #9: 10. 
11. Viral load at Anal Pap Test: 11. 
12. Date viral load from item #11: 12. 
13. On ART at Anal Pap Test: 13. 
14. Ever on ART:   1=no   2=yes 14. 
15. Anal Disease on physical examination: 1=no  2=yes 15. 
16. History of HSV; 1=no  2=yes 16. 
17. History of genital warts  1=no  2=yes 17. 
18. History of abnormal cervical Pap: 1=no  2=yes 18. 
19. Date abnormal cervical Pap: 19. 
20. Abnormal cervical Pap result: 20. 
21. Other anal/GU disease (type): 21. 
22. Date Anal Pap: 22. 
23. Results of Anal Pap: 23. 
24. Date HRA: 24. 
25. Results HRA: 25. 
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Repeat Anal Pap Collection Data Sheet 
26. Repeat Anal Pap #: 26. 
27. Date repeat Anal Pap: 27. 
28. Age at repeat Pap (years): 28. 
29. Reason repeat Anal Pap:  1=annual screening  2=f/u of abn pap  
3=previous insufficient sample 4=other(explain) 
29. 
30. CD4 nadir: 30. 
31. Date CD4 nadir: 31. 
32. CD4 at repeat Anal Pap Test 32. 
33. Date CD4 from item #9: 33. 
34. Decline in CD4 since last Pap: 1=no 2=yes 34. 
35. Viral load at this Anal Pap Test: 35. 
36. Date viral load from item #11: 36. 
37. On ART at this Anal Pap Test: 37. 
38. Newly on ART since last Pap:   1=no   2=yes 38. 
39. Anal Disease on physical examination at Pap: 1=no  
2=yes 
39. 
40. New dx of HSV since last Pap: 1=no 2=yes 40. 
41. New dx of Genital warts since last Anal Pap: 1=no 
2=yes 
41. 
42. New abnormal Pap since last Anal Pap: 1=no 2=yes 42. 
43. Date new abnormal cervical Pap: 43. 
44. Abnormal cervical Pap result: 44. 
45. Other new anal/GU disease (type): 45. 
46. Results of Anal Pap: 46. 
47. Date HRA: 47. 
48. Results HRA: 48. 
 
